Feline Immunodeficiency Virus (FIV)
Under development Stay tuned
Feline Immunodeficiency Virus (FIV) is the causative agent of feline AIDS (FAIDS). In its natural state, Feline Immunodeficiency Virus can infect more than 20 species of cats, including domestic cats, wild cats, lions, tigers and leopards.
At this stage, FIV has become widespread worldwide, and even the infection rate of stray cats in individual countries is 100%.
Similar to HIV infection in humans, FIV does not cause specific clinical symptoms in the host at the beginning of the infection process, but the process of virus replication in the body gradually causes immunosuppression in the host, resulting in opportunistic infections including other viruses, bacteria, parasites, etc.
Common symptoms in cats infected with FIV are:
- Stomatitis.
- Gingivitis.
- Persistent fever.
- Decreased appetite.
- Weakness.
- Progressive emaciation.
- Elevated body temperature.
- Skin pimples.
- Skin disease.
- Urinary tract infections.
- Upper respiratory tract infections and a generalized defect in CD4+ T lymphocyte function.
Unfortunately, there are still no treatment options available worldwide that can target FIV.
MT-2602 is a novel, selective inhibitor of the FIV capsid that disrupts the FIV capsid, a multimeric shell necessary for viral replication, at multiple stages of the viral life cycle.
MUTIAN is developing it as a potential long-acting therapy. Results from preliminary clinical studies of the subcutaneous formulation show that MT-2602 has potent antiviral activity and rapidly reduces viral load after a single subcutaneous dose.
At day 10 post-dose, FIV RNA was significantly lower in patients in all dose groups treated with MT-2602 compared to placebo. MT-2602 has a half-life of approximately 12 days, and high and low-fat diets had no effect on PK. These data support the development of MT-2602 as an oral weekly formulation without consideration of food effects. MT-2602 is generally safe and well tolerated, with no cats experiencing serious adverse effects in the current clinical studies.